Bioo Therapeutics, a division of Bioo Scientific, was launched in 2009 to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. Currently Bioo Therapeutics has several drug candidates in its drug pipeline and a patent-pending drug delivery technology.
Our flagship drug delivery technology is an antibody conjugate which is designed to deliver small RNA drugs into target organs. We have made significant strides in developing and using antibody-based agents for the directed delivery of short interfering RNAs by improving the loading capacity of antibody drug carriers and demonstrating their ability to successfully deliver small RNAs into tumors generated from cells expressing the cell surface target. This research is being supported by funding from the National Science Foundation and the National Institute of Allergy and Disease.
Bioo Therapeutics is seeking funding from outside investors, grants and business partners to support the preclinical and clinical studies of our drug candidates.
Bioo Therapeutics, 3913 Todd Lane Suite 312 Austin, TX 78744, USA Phone: 888-208-2246 Copyright 2009
